Olanamo contains Olaparib, an oral poly(ADP-ribose) polymerase (PARP) inhibitor used primarily for the treatment of certain types of cancers, including ovarian, breast, prostate, and pancreatic cancers, particularly in patients with BRCA1/2 mutations. Olaparib helps prevent cancer cell repair, leading to cancer cell death, while sparing normal cells.

Mechanism of Action

• Olaparib inhibits the PARP enzymes, which are involved in repairing single-strand DNA breaks.

• In cancer cells with BRCA1/2 mutations, the homologous recombination repair pathway is already defective.

• Blocking PARP leads to accumulation of DNA damage, causing cancer cell death (synthetic lethality).

  Uses

  • Treatment of BRCA-mutated ovarian cancer (advanced or recurrent).

  • Treatment of metastatic BRCA-mutated breast cancer.

  • Treatment of metastatic castration-resistant prostate cancer with BRCA mutations.

  • Maintenance therapy in patients with platinum-sensitive cancers to delay progression.

    Adverse Effects

    • Nausea, vomiting, diarrhea

    • Fatigue or weakness

    • Anemia or low blood counts

    • Loss of appetite